However, whether specific S100 signatures in patients’ body fluids could discriminate the different stages of NAFLD and ideally predict the risk of progression to severe stages, e.g., steatosis to NASH or NASH to cirrhosis, remains currently unclear, but future studies should provide important insights in this regard. The gene discussed is S100A1; the disease is metabolic dysfunction-associated steatotic liver disease.